Temporary flying restrictions are per Service specific policy.
Currently the safety and effectiveness of IXIARO® for the pediatric population has not been established. The FDA has ongoing studies, the FDA-approved IXIARO® is only for use in patients 17 years of age or older.
JE-VAX®, the only vaccine for those younger than 17 years of age, is no longer available. ACIP guidelines suggest the following options for obtaining JE vaccine for U.S. children deemed at risk for JE exposure.